Visual Assessment for Non-Culprit Lesion Revascularization

There is evidence in favor of complete revascularization in the context of ST elevation MI with multivessel disease where primary PCI has been successful. 

Estimación visual para revascularizar las lesiones no culpables

However, the small print in these studies should be read carefully. Should revascularization be completed during index intervention, index hospitalization or after discharge? Should complete revascularization be based on visual assessment, quantitative angiography, intravascular imaging, invasive functional criteria, or stress test imaging? 

The latest studies tend to simplify: non-culprit lesions can be revascularized after primary PCI. 

The present study, recently published in JACC, follows the same idea: defining non-culprit lesions with quantitative angiography.

In 4041 patients from the COMPLETE study, non-culprit lesions were analyzed mostly with quantitative angiography (n=3851). 


Read also: Ticagrelor to Improve Venous Graft Patency.


The pre-specified analysis determined the impact of stenosis severity >60% vs. <60% by quantitative angiography on the primary end point of cardiovascular death or new MI.

The secondary end point was a combination of cardiovascular death, new MI and ischemia driven revascularization.

Primary end point was reduced in 2479 patients presenting >60% stenosis severity by quantitative angiography (2.5% vs. 4.2%; HR: 0.61; CI 95%: 0.47 to 0.79) but not in the 1372 patients with non-culprit stenosis severity <60% (3% vs 2.9%; HR 1.04, CI 95%; 072 to 1.5).


Read also: Same Contrast Dose, Different Risk of Kidney Injury, Depending on Procedure.


The secondary end point saw similar outcomes.

Conclusion

In patients undergoing ST elevation acute coronary syndrome with multivessel disease, complete revascularization reduces events when quantitative angiography of non-culprit lesions shows >60% stenosis severity. 

Título original: Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease.

Referencia: Tej Sheth et al. J Am Coll Cardiol 2020;76:1277–86. https://doi.org/10.1016/j.jacc.2020.07.034.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...